Products with Anti-inflammatory skin diseases bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1071 | Ginsenoside Rh3 |
| Ginsenoside Rh3 is a bacterial metabolite of Ginsenoside Rg5, Rh3 has anti-inflammatory effect in microglia by modulating AMPK and its downstream signaling pathways, it may improve chronic dermatitis or psoriasis by the regulation of IL-1β and TNF-α produced by macrophage cells and of IFN-γ produced by Th cells. Rg5 and Rh3 inhibited acetylcholinesterase activity in a dose-dependent manner, with IC50 values of 18.4 and 10.2 uM, respectively, they may protect memory deficit by inhibiting AChE activity and increasing BDNF expression and CREB activation. | |
| BCN1221 | Glabridin |
| Glabridin is a GABAA receptor positive modulator promoting fatty acid oxidation and improving learning and memory, which has antioxidative,anti-inflammatory, antimalarial, estrogen receptor agonism, anti-metastasis, anti-melanogenesis and neuroprotective effects. Glabridin may possess a therapeutic effect on metabolic disorders( such as diabetes and hyperglycemia), by modulating glucose metabolism through AMPK in skeletal muscle cells. | |
| BCN1708 | Catalpalactone |
| 1. Catalpalactone can inhibit dopamine biosynthesis by reducing tyrosine hydroxylase (TH) and aromatic-l-amino acid decarboxylase (AADC) activities and enhance L-DOPA- induced cytotoxiciy in PC12 cells. 2. Catalpalactone displays good cytotoxicity activities against two human tumor cell lines(MCF-7,BxPC3). 3. Catalpalactone exhibits significant inhibitory activity against 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced Epstein-Barr virus early antigen (EBV-EA) activation in Raji cells. 4. Catapalactone exhibits potent inhibitory effects on lipopolysaccharide-induced NO synthesis in RAW 264.7 cells , with IC50 values of 9.80 microM. 5. Catalpalactone exhibits high antitermitic activity. | |
| BCN2167 | Fingolimod hydrochloride |
| Fingolimod hydrochloride is an oral sphingosine-1-phosphate analogue that was approved by the FDA in 2010 for the treatment of relapsing forms of multiple sclerosis (MS). Fingolimod hydrochloride , a pak1 activator, can inhibit astemizole-induced hypertrophy and cytotoxicity in H9c2 cells, suggests that antihistamine-induced cardiac adverse effects are associated with pak1 expression and function.The gels containing 0.50% fingolimod hydrochloride (FNGL) and FNGL 0.50% plus 6% colloidal oatmeal have potential for the treatment of atopic dermatitis (AD). | |
